The US Food and Drug Administration has expanded the approved indications for Boston Scientific’s SYNERGY BP everolimus-eluting platinum chromium coronary stent to include patients at high risk for bleeding, the company announced on 11 August.
This labeling expansion makes SYNERGY BP the first and only stent platform approved in the US for patients at high risk of bleeding.